Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification
暂无分享,去创建一个
Jingjing Yu | Jennifer E Sager | Isabelle Ragueneau-Majlessi | Nina Isoherranen | N. Isoherranen | Jingjing Yu | I. Ragueneau-Majlessi | J. Sager
[1] P. Neuvonen,et al. Glucuronidation Converts Clopidogrel to a Strong Time‐Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions , 2014, Clinical pharmacology and therapeutics.
[2] M. Rowland,et al. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.
[3] Harvey J Clewell,et al. Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[4] M Rowland,et al. The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review , 2012, Clinical pharmacology and therapeutics.
[5] A Rostami-Hodjegan,et al. Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. , 2013, Biopharmaceutics & drug disposition.
[6] Filippos Kesisoglou,et al. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[7] Tristan S. Maurer,et al. A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro , 2008, Drug Metabolism and Disposition.
[8] S. Yeleswaram,et al. Predicting Drug–Drug Interactions Involving Multiple Mechanisms Using Physiologically Based Pharmacokinetic Modeling: A Case Study With Ruxolitinib , 2015, Clinical pharmacology and therapeutics.
[9] Magang Shou,et al. Prediction of Human Drug-Drug Interactions from Time-Dependent Inactivation of CYP3A4 in Primary Hepatocytes Using a Population-Based Simulator , 2009, Drug Metabolism and Disposition.
[10] Daniel Röshammar,et al. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. , 2011, British journal of clinical pharmacology.
[11] Prasad S. Dhurjati,et al. Maximum Recommended Dosage of Lithium for Pregnant Women Based on a PBPK Model for Lithium Absorption , 2012, Adv. Bioinformatics.
[12] Diansong Zhou,et al. Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents , 2014, Biopharmaceutics & drug disposition.
[13] Filippos Kesisoglou,et al. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[14] Shiew-Mei Huang,et al. Quantitative Evaluation of Pharmacokinetic Inhibition of CYP3A Substrates by Ketoconazole: A Simulation Study , 2009, Journal of clinical pharmacology.
[15] Masoud Jamei,et al. Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model , 2015, Front. Immunol..
[16] William J. Jusko,et al. Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model , 2015, Pharmaceutical Research.
[18] Sebastian Polak,et al. Assessment of inter-individual variability in predicted phenytoin clearance , 2009, European Journal of Clinical Pharmacology.
[19] Ying-Hong Wang,et al. Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors , 2010, Drug Metabolism and Disposition.
[20] F. Theil,et al. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. , 2000, Journal of pharmaceutical sciences.
[21] T Ishizaki,et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.
[22] M. Jamei,et al. A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine , 2013, Clinical Pharmacokinetics.
[23] Sebastian Polak,et al. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[24] Shiew-Mei Huang,et al. Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation , 2012, Journal of clinical pharmacology.
[25] L. Kuepfer,et al. Using Expression Data for Quantification of Active Processes in Physiologically Based Pharmacokinetic Modeling , 2012, Drug Metabolism and Disposition.
[26] R. Obach,et al. DMD054031 1975..1993 , 2013 .
[27] Shiew-Mei Huang,et al. Predicting Nonlinear Pharmacokinetics of Omeprazole Enantiomers and Racemic Drug Using Physiologically Based Pharmacokinetic Modeling and Simulation: Application to Predict Drug/Genetic Interactions , 2014, Pharmaceutical Research.
[28] Karthik Venkatakrishnan,et al. Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions , 2007, Drug Metabolism and Disposition.
[29] Stephen D. Hall,et al. Prediction of In Vivo Clearance and Associated Variability of CYP2C19 Substrates by Genotypes in Populations Utilizing a Pharmacogenetics-Based Mechanistic Model , 2015, Drug Metabolism and Disposition.
[30] Leon Aarons,et al. Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data , 2015, British journal of clinical pharmacology.
[31] Ping Zhao,et al. Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. , 2014, British journal of clinical pharmacology.
[32] L. Berezhkovskiy,et al. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. , 2004, Journal of pharmaceutical sciences.
[33] Ghanashyam Joshi,et al. Have physiologically-based pharmacokinetic models delivered? , 2011, Expert opinion on drug metabolism & toxicology.
[34] Jennifer B Dressman,et al. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[35] L Zhang,et al. Predicting Drug Interaction Potential With a Physiologically Based Pharmacokinetic Model: A Case Study of Telithromycin, a Time‐Dependent CYP3A Inhibitor , 2012, Clinical pharmacology and therapeutics.
[36] Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products , 2012 .
[37] N. Djebli,et al. Physiologically Based Pharmacokinetic Modeling for Sequential Metabolism: Effect of CYP2C19 Genetic Polymorphism on Clopidogrel and Clopidogrel Active Metabolite Pharmacokinetics , 2015, Drug Metabolism and Disposition.
[38] Hugh A. Barton,et al. Physiologically Based Pharmacokinetic Prediction of Telmisartan in Human , 2014, Drug Metabolism and Disposition.
[39] John Crison,et al. Predicting feasibility and characterizing performance of extended-release formulations using physiologically based pharmacokinetic modeling. , 2012, Therapeutic delivery.
[40] Brian Tomlinson,et al. Clinical Pharmacokinetics of Buffered Propranolol Sublingual Tablet (Promptol™)—Application of a New “Physiologically Based” Model to Assess Absorption and Disposition , 2013, The AAPS Journal.
[41] B Agoram,et al. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.
[42] Sara K Quinney,et al. Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite , 2009, Drug Metabolism and Disposition.
[43] M. Rowland,et al. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.
[44] Tycho Heimbach,et al. A Simplified PBPK Modeling Approach for Prediction of Pharmacokinetics of Four Primarily Renally Excreted and CYP3A Metabolized Compounds During Pregnancy , 2013, The AAPS Journal.
[45] N Parrott,et al. Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective , 2015, Clinical pharmacology and therapeutics.
[46] K. Pang,et al. THE ROLES OF TRANSPORTERS AND ENZYMES IN HEPATIC DRUG PROCESSING , 2005, Drug Metabolism and Disposition.
[47] Masoud Jamei,et al. Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. , 2013, Journal of pharmaceutical sciences.
[48] Ping Wang,et al. A physiologically based pharmacokinetic model characterizing mechanism-based inhibition of CYP1A2 for predicting theophylline/antofloxacin interaction in both rats and humans. , 2011, Drug metabolism and pharmacokinetics.
[49] Shiew-Mei Huang,et al. The utility of modeling and simulation in drug development and regulatory review. , 2013, Journal of pharmaceutical sciences.
[50] N. Wood,et al. Pharmacokinetics of Voriconazole Administered Concomitantly with Fluconazole and Population-Based Simulation for Sequential Use , 2011, Antimicrobial Agents and Chemotherapy.
[51] Malcolm Rowland,et al. Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.
[52] Malcolm Rowland,et al. Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential , 2012, Pharmaceutical Research.
[53] M Jamei,et al. Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings. , 2012, Current drug metabolism.
[54] Amin Rostami-Hodjegan,et al. Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus. , 2012, Current drug metabolism.
[55] Amin Rostami-Hodjegan,et al. Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure , 2013, European Journal of Clinical Pharmacology.
[56] N. Oberlies,et al. Physiologically Based Pharmacokinetic Modeling Framework for Quantitative Prediction of an Herb–Drug Interaction , 2014, CPT: pharmacometrics & systems pharmacology.
[57] Y. Sugiyama,et al. Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver , 2013, Clinical pharmacology and therapeutics.
[58] Chuang Lu,et al. Assessment of cytochrome P450‐mediated drug–drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation , 2014, Biopharmaceutics & drug disposition.
[59] Dae-Duk Kim,et al. In vitro–in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications , 2014, Drug development and industrial pharmacy.
[60] D. Thakker,et al. A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children , 2014, Clinical Pharmacokinetics.
[61] Maurice Dickins,et al. Maraviroc: in vitro assessment of drug-drug interaction potential. , 2008, British journal of clinical pharmacology.
[62] Patrick Poulin,et al. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design. , 2015, Journal of pharmaceutical sciences.
[63] Harvey J. Clewell,et al. A Semiphysiologically Based Pharmacokinetic Modeling Approach to Predict the Dose-Exposure Relationship of an Antiparasitic Prodrug/Active Metabolite Pair , 2012, Drug Metabolism and Disposition.
[64] Jianghong Fan,et al. PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. , 2010, Current drug metabolism.
[65] B. Feng,et al. Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions , 2012, Pharmaceutical Research.
[66] Ping Zhao,et al. Dealing with the complex drug-drug interactions: towards mechanistic models. , 2015, Biopharmaceutics & drug disposition.
[67] Suman Sen,et al. Time‐Dependent Inhibition and Induction of Human Cytochrome P4503A4/5 by an Oral IAP Antagonist, LCL161, In Vitro and In Vivo in Healthy Subjects , 2013, Journal of clinical pharmacology.
[68] Denis Duboule,et al. Contents , 2015, Mechanisms of Development.
[69] Jennifer E Sager,et al. Fluoxetine and norfluoxetine mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19 and CYP3A4 , 2014, Clinical pharmacology and therapeutics.
[70] Hugh A Barton,et al. Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond , 2013, Expert opinion on drug metabolism & toxicology.
[71] Masahiro Iwaki,et al. Application of a Physiologically Based Pharmacokinetic Model Informed by a Top-Down Approach for the Prediction of Pharmacokinetics in Chronic Kidney Disease Patients , 2014, The AAPS Journal.
[72] Thomas Singer,et al. Development of a Physiologically Based Model for Oseltamivir and Simulation of Pharmacokinetics in Neonates and Infants , 2011, Clinical pharmacokinetics.
[73] A. D. Rodrigues,et al. Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide , 2015, Drug Metabolism and Disposition.
[74] Aleksandra Galetin,et al. Rationalizing underprediction of drug clearance from enzyme and transporter kinetic data: from in vitro tools to mechanistic modeling. , 2014, Methods in molecular biology.
[75] Benoit Blanchet,et al. Determination of the Most Influential Sources of Variability in Tacrolimus Trough Blood Concentrations in Adult Liver Transplant Recipients: A Bottom-Up Approach , 2014, The AAPS Journal.
[76] Amin Rostami-Hodjegan,et al. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.
[77] Anna M. Wu,et al. A Predictive Model of Therapeutic Monoclonal Antibody Dynamics and Regulation by the Neonatal Fc Receptor (FcRn) , 2005, Annals of Biomedical Engineering.
[78] Ping Xu,et al. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions. , 2013, Journal of pharmaceutical sciences.
[80] D. Leahy,et al. Progress in simulation modelling for pharmacokinetics. , 2003, Current topics in medicinal chemistry.
[81] Y. Zhang,et al. Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model , 2015, European Journal of Drug Metabolism and Pharmacokinetics.
[82] Erik Sjögren,et al. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[83] Rui Chen,et al. Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling , 2012, Acta Pharmacologica Sinica.
[84] Sebastian Polak,et al. Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.
[85] Alex Phipps,et al. Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction , 2009, Drug Metabolism and Disposition.
[86] S D Hall,et al. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[87] Amin Rostami-Hodjegan,et al. Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model , 2011, Xenobiotica; the fate of foreign compounds in biological systems.
[88] Jian Lin,et al. Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin , 2013, Drug Metabolism and Disposition.
[89] Nikolaos Tsamandouras,et al. Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk , 2014, Pharmaceutical Research.
[90] U. Christians,et al. Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content , 2013, CPT: pharmacometrics & systems pharmacology.
[91] Li Liu,et al. Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model , 2015, Clinical Pharmacokinetics.
[92] M. Sheffer,et al. CHARACTERIZATION AND APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS IN RISK ASSESSMENT , 2011 .
[93] Malcolm Rowland,et al. Clearance concepts in pharmacokinetics , 1973, Journal of Pharmacokinetics and Biopharmaceutics.
[94] S. Hall,et al. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[95] J. Gallo,et al. Multiscale Design of Cell-Type–Specific Pharmacokinetic/Pharmacodynamic Models for Personalized Medicine: Application to Temozolomide in Brain Tumors , 2014, CPT: pharmacometrics & systems pharmacology.
[96] Atsushi Kambayashi,et al. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[97] K. Pang,et al. Why we need proper PBPK models to examine intestine and liver oral drug absorption. , 2012, Current drug metabolism.
[99] L Zhang,et al. Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.
[100] Yuan Chen,et al. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions Involving Inhibitory Metabolite: A Case Study of Amiodarone , 2015, Drug Metabolism and Disposition.
[101] S-M Huang,et al. Regulatory Experience With Physiologically Based Pharmacokinetic Modeling for Pediatric Drug Trials , 2012, Clinical pharmacology and therapeutics.
[102] Malcolm Rowland,et al. Lumping of Whole-Body Physiologically Based Pharmacokinetic Models , 1998, Journal of Pharmacokinetics and Biopharmaceutics.
[103] Thuy Tran,et al. Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development , 2013, Drug Metabolism and Disposition.
[104] William J. Jusko,et al. Applications of minimal physiologically-based pharmacokinetic models , 2012, Journal of Pharmacokinetics and Pharmacodynamics.
[105] Patrick Poulin,et al. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. , 2002, Journal of pharmaceutical sciences.
[106] Yuichi Sugiyama,et al. Analysis of the Repaglinide Concentration Increase Produced by Gemfibrozil and Itraconazole Based on the Inhibition of the Hepatic Uptake Transporter and Metabolic Enzymes , 2013, Drug Metabolism and Disposition.
[107] Wilhelm Huisinga,et al. Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[108] Jashvant D Unadkat,et al. Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo. , 2014, Biochemical pharmacology.
[109] He Lian,et al. Profiling biopharmaceutical deciding properties of absorption of lansoprazole enteric-coated tablets using gastrointestinal simulation technology. , 2013, International journal of pharmaceutics.
[110] Hannah M. Jones,et al. Modelling and PBPK Simulation in Drug Discovery , 2009, The AAPS Journal.
[111] M Rowland,et al. Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions , 2012, Clinical pharmacology and therapeutics.
[112] Paolo Vicini,et al. Physiologically based pharmacokinetic model of midazolam disposition during pregnancy , 2008, 2008 30th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
[113] François Bouzom,et al. Comparing translational population‐PBPK modelling of brain microdialysis with bottom‐up prediction of brain‐to‐plasma distribution in rat and human , 2014, Biopharmaceutics & drug disposition.
[114] Wojciech Krzyzanski,et al. Simplification of Complex Physiologically Based Pharmacokinetic Models of Monoclonal Antibodies , 2014, The AAPS Journal.
[115] Andrea N Edginton,et al. Physiologically Based Pharmacokinetic Modeling of Impaired Carboxylesterase-1 Activity: Effects on Oseltamivir Disposition , 2014, Clinical Pharmacokinetics.
[116] Markus Luster,et al. Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic Model , 2010, Journal of Nuclear Medicine.
[117] Stefan Willmann,et al. Defining the Role of Macrophages in Local Moxifloxacin Tissue Concentrations using Biopsy Data and Whole-Body Physiologically Based Pharmacokinetic Modelling , 2009, Clinical pharmacokinetics.
[118] Li Liu,et al. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[119] Fahima Nekka,et al. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. , 2010, Journal of pharmaceutical sciences.
[120] Wilhelm Huisinga,et al. Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[121] F. Theil,et al. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. , 2001, Journal of pharmaceutical sciences.
[122] Hugh A. Barton,et al. A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling , 2014, Journal of Pharmacokinetics and Pharmacodynamics.
[123] Dhaval K. Shah,et al. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human , 2011, Journal of Pharmacokinetics and Pharmacodynamics.
[124] Lu Gaohua,et al. A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. , 2012, British journal of clinical pharmacology.
[125] M Jamei,et al. Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. , 2009, Current drug metabolism.
[126] Anna Tostevin,et al. An observational multi-cohort study on the use and safety of Combivir scored tablets among HIV-infected children and adolescents. Report to the European Medicines Agency (EMA)/ Committee for Medicinal Products for Human Use (CHMP) , 2014 .
[127] Jian Lin,et al. Mechanism-Based Pharmacokinetic Modeling to Evaluate Transporter-Enzyme Interplay in Drug Interactions and Pharmacogenetics of Glyburide , 2014, The AAPS Journal.
[128] Yves Bertrand,et al. Influence of Dosing Schedule on Organ Exposure to Cyclosporin in Pediatric Hematopoietic Stem Cell Transplantation: Analysis with a PBPK Model , 2010, Pharmaceutical Research.
[129] Masoud Jamei,et al. Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin. , 2013, Journal of pharmaceutical sciences.
[130] Sieto Bosgra,et al. Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[131] M. Jamei,et al. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.
[132] Thierry Lavé,et al. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. , 2005, Basic & clinical pharmacology & toxicology.
[133] D J Rance,et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.
[134] Tycho Heimbach,et al. Case Studies for Practical Food Effect Assessments across BCS/BDDCS Class Compounds using In Silico, In Vitro, and Preclinical In Vivo Data , 2012, The AAPS Journal.
[135] Khaled Abduljalil,et al. Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations , 2014, Drug Metabolism and Disposition.
[136] Marco Siccardi,et al. Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV , 2015, Clinical Pharmacokinetics.
[137] Amin Rostami-Hodjegan,et al. Physiologically based pharmacokinetic (PBPK) modeling: it is here to stay! , 2012, Biopharmaceutics & drug disposition.
[138] P. Zhao,et al. A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction , 2012, CPT: pharmacometrics & systems pharmacology.
[139] Hugh A. Barton,et al. Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data , 2012, Drug Metabolism and Disposition.
[140] I Zineh,et al. Physiologically Based Pharmacokinetic Modeling: From Regulatory Science to Regulatory Policy , 2014, Clinical pharmacology and therapeutics.
[141] Athanassios Iliadis,et al. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[142] Yves Bertrand,et al. Links Between Cyclosporin Exposure in Tissues and Graft-Versus-Host Disease in Pediatric Bone Marrow Transplantation: Analysis by a PBPK Model , 2010, Pharmaceutical Research.
[143] Masoud Jamei,et al. Simulation of Monoclonal Antibody Pharmacokinetics in HumansUsing a Minimal Physiologically Based Model , 2014, The AAPS Journal.
[144] Marjo Yliperttula,et al. Challenges of Using In Vitro Data for Modeling P-Glycoprotein Efflux in the Blood-Brain Barrier , 2013, Pharmaceutical Research.
[145] Manuela Pavan,et al. Prediction of dose-hepatotoxic response in humans based on toxicokinetic/toxicodynamic modeling with or without in vivo data: a case study with acetaminophen. , 2013, Toxicology letters.
[146] William J. Jusko,et al. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model , 2014, Journal of Pharmacokinetics and Pharmacodynamics.
[147] Lei Zhang,et al. Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations , 2014, Clinical Pharmacokinetics.
[148] William J. Jusko,et al. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies , 2013, Journal of Pharmacokinetics and Pharmacodynamics.
[149] K Rowland-Yeo,et al. Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine , 2013, CPT: pharmacometrics & systems pharmacology.
[150] U. Hofmann,et al. A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation. , 2015, Journal of pharmaceutical sciences.
[151] J B Houston,et al. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.
[152] K. Sandy Pang,et al. Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[153] Charles A Timchalk,et al. A multi-route model of nicotine-cotinine pharmacokinetics, pharmacodynamics and brain nicotinic acetylcholine receptor binding in humans. , 2013, Regulatory toxicology and pharmacology : RTP.
[154] R K Jain,et al. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. , 1995, Cancer research.
[155] Emmanuel Scheubel,et al. Physiologically Based Absorption Modelling to Predict the Impact of Drug Properties on Pharmacokinetics of Bitopertin , 2014, The AAPS Journal.
[156] Y. Zhang,et al. Prediction of Pharmacokinetics and Penetration of Moxifloxacin in Human with Intra-Abdominal Infection Based on Extrapolated PBPK Model , 2015, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.
[157] John A Wagner,et al. Effect of Different Durations and Formulations of Diltiazem on the Single‐Dose Pharmacokinetics of Midazolam: How Long Do We Go? , 2011, Journal of clinical pharmacology.
[158] J. Kindt,et al. Understanding pharmacokinetic food effects using molecular dynamics simulation coupled with physiologically based pharmacokinetic modeling , 2012, Biopharmaceutics & drug disposition.
[159] A. Vinks,et al. The Future of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure in Pregnant Women , 2013, CPT: pharmacometrics & systems pharmacology.
[160] Leon Aarons,et al. A Physiologically Based Pharmacokinetic Model for Clobazam and Stiripentol in Adults and Children , 2014, Pharmaceutical Research.
[161] Franco Lombardo,et al. Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance , 2013, Journal of clinical pharmacology.
[162] M. Jamei,et al. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. , 2010, Toxicology.
[163] Bernd Meibohm,et al. Tools for predicting the PK/PD of therapeutic proteins , 2015, Expert opinion on drug metabolism & toxicology.
[164] Hefei Zhang,et al. Application of Physiologically Based Absorption Modeling to Formulation Development of a Low Solubility, Low Permeability Weak Base: Mechanistic Investigation of Food Effect , 2014, AAPS PharmSciTech.
[165] Kannan Krishnan,et al. Cutting Edge PBPK Models and Analyses: Providing the Basis for Future Modeling Efforts and Bridges to Emerging Toxicology Paradigms , 2012, Journal of toxicology.
[166] Diansong Zhou,et al. Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects , 2015, Journal of clinical pharmacology.
[167] Franco Lombardo,et al. Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 1: Volume of Distribution at Steady State , 2013, Journal of clinical pharmacology.
[168] David A Mankoff,et al. Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study , 2015, Drug Metabolism and Disposition.
[169] Zhe-Yi Hu,et al. Physiologically based pharmacokinetic modelling and in vivo [I]/Ki accurately predict P‐glycoprotein‐mediated drug‐drug interactions with dabigatran etexilate , 2014, British journal of pharmacology.
[170] Hefei Zhang,et al. Utility of Physiologically Based Modeling and Preclinical In Vitro/In Vivo Data to Mitigate Positive Food Effect in a BCS Class 2 Compound , 2013, AAPS PharmSciTech.
[171] Ping Zhao,et al. A Physiologically Based Pharmacokinetic Model to Predict Disposition of CYP2D6 and CYP1A2 Metabolized Drugs in Pregnant Women , 2013, Drug Metabolism and Disposition.
[172] Yuan Chen,et al. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies , 2012, Biopharmaceutics & drug disposition.
[173] H. E. Buist,et al. Characterization and application of physiologically based pharmacokinetic models in risk assessment , 2010 .
[174] J R Gillette. FACTORS AFFECTING DRUG METABOLISM , 1971, Annals of the New York Academy of Sciences.
[175] Marco Siccardi,et al. Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach , 2013, Clinical Pharmacokinetics.